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Background: Cytomegalovirus is the most common pathogen causing congenital infection and can result in
significant neurodevelopmental adverse outcomes. For this reason, it is the standard of care in many regions to
treat congenital cytomegalovirus infection involving the brain with six weeks of ganciclovir. There have been no
reports in the published literature of significant cytomegalovirus neonatal infection in infants previously treated for
congenital infection.
Case presentation: A preterm male infant with congenital symptomatic cytomegalovirus infection was initially
treated with over 8 weeks of ganciclovir between the ages of 3 and 14 weeks. At four months chronologic age, just
prior to planned discharge, he developed an episode of life-threatening multisystem cytomegalovirus disease
notable for severe pneumonitis, encephalitis, hepatitis, and disseminated intravascular coagulation. This disease
resolved after re-treatment with a prolonged course of intravenous ganciclovir and oral valganciclovir.
Conclusions: Clinicians should be aware of the possibility of recurrence of congenital cytomegalovirus infection,
especially in preterm infants. Serial plasma cytomegalovirus viral load monitoring may have a role in the
management of premature infants treated with ganciclovir; had the diagnosis of recrudescent cytomegalovirus
infection been considered sooner, specific therapy might have been more quickly initiated and perhaps further
morbidity would have been prevented.
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Cytomegalovirus (CMV) is currently the most common
pathogen causing congenital (fetal) infection. Sequelae of
congenital infection include significant cognitive deficits,
psychomotor impairment and deafness. As a result, it is
now the standard of care in many regions to treat congeni-
tal CMV infection (especially that involving the central
nervous system) with at least six weeks of ganciclovir in an
effort to minimize neurodevelopmental sequelae, given the
decrease in hearing loss seen with this therapy in a ran-
domized controlled trial [1].
CMV infection can also be acquired in the perinatal or
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reproduction in any medium, provided the orhorizontal close contact, blood product transfusions, or via
ingestion of breast milk contaminated with the virus.
Perinatally- or postnatally-acquired CMV infection, in
contrast to congenital infection, more frequently pre-
sents with a ‘sepsis-like syndrome’ or severe pneumon-
itis [2]; numerous case reports document severe illness
caused by postnatally-acquired CMV in very low birth
weight infants [3,4].
Case presentation
The patient was a 730 g male born at 28+1 weeks of gesta-
tion, the product of a spontaneous dichorionic diamniotic
twin pregnancy complicated by severe growth restriction
in both fetuses. Leukopenia, thrombocytopenia, and mild
bilateral ventriculomegaly were present at birth, which
raised suspicion for congenital infection; a urine samplel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Blood work demonstrated very mildly elevated serum
conjugated bilirubin (13 micromol/L) on the day of birth
that progressively increased; there was no elevation of
liver transaminases, increase in prothrombin time, or
clinically evident bleeding. CMV infection of both pla-
centas was confirmed using immunohistochemistry and
both chronic hemorrhagic lymphoplasmacytic villitis and
villous vasculitis was seen on pathology. Consequently,
treatment with ganciclovir (6 mg/kg/dose IV q12h) was
initiated at 19 days of age. It should be noted that his abso-
lute neutrophil count (ANC) transiently dropped below
1000/microL at 17 days of age, before antivirals were
started. On day 2 of ganciclovir treatment, the ANC de-
creased again to 800/microL, which resulted in a 36-hour
suspension of antiviral therapy.
At just under 5 weeks chronologic age, after 13 days
of ganciclovir therapy, when his absolute neutrophil
count was normal, the patient developed sepsis in asso-
ciation with an Enterococcus faecalis central line infec-
tion. The peripherally-inserted central catheter was not
removed promptly, his neutrophil count briefly dropped
to 400/microL, the ganciclovir was held, and he experi-
enced a pulmonary haemorrhage four days later. With
antibacterial therapy and removal of the offending ven-
ous catheter, his condition rapidly stabilized. His plasma
CMV viral load (VL) was determined to be 1 × 106
copies/mL after eleven days off treatment; ganciclovir
treatment was resumed after a two-week hiatus and contin-
ued for an additional 6 weeks through a replacement cen-
tral venous catheter. Due to the neutropaenia associated
with his septic deterioration, filgrastim (granulocyte colony
stimulating factor) therapy was begun the day prior to the
reinitiation of ganciclovir therapy and was given intermit-
tently whenever the patient’s neutrophils appeared to be in
decline, though the ANC did not go below 1000/microL
during the remainder of the ganciclovir treatment course.
During this time, the baby was mainly fed with frozen-
thawed breast milk. For prematurity-associated anaemia,
he was transfused a total of 785 mL (4 donors) of leuko-
reduced irradiated blood, of which only 341 mL (2 donors)
was received when not on ganciclovir therapy.
Three weeks after finishing the ganciclovir, at 4 months
chronologic age, shortly before the time of his planned
hospital discharge, the infant developed progressive re-
spiratory distress. Cefazolin and gentamicin were started;
blood cultures were negative, and, at this time, the abso-
lute neutrophil count was normal. He was stable enough
to be electively intubated for laser eye surgery, but sub-
sequently developed increased respiratory requirements.
His chest X-ray showed bilateral mixed airspace and
interstitial opacities, an endotracheal tube aspirate showed
‘few’ WBCs on the gram stain, and aspirate cultures grew
K. pneumoniae (sensitive to cefazolin), so a presumptivediagnosis of ventilator-associated pneumonia was made.
The cerebrospinal fluid was sampled and was found to
have 13 WBC/hpf (2% neutrophils, 48% lymphocytes, 50%
monocytes), 2 RBC/hpf, glucose of 2.8 mmol/L, and pro-
tein of 1.3 g/L. His condition worsened, and he was
switched to cefotaxime, without demonstrable improve-
ment. He developed respiratory failure requiring ventila-
tion with high frequency oscillatory ventilation and nitric
oxide therapy was initiated. Significant hepatosplenomegaly
was observed for the first time, accompanied by elevated
AST and ALT (273 U/L and 221 U/L, respectively), and
the patient developed disseminated intravascular coagula-
tion. Repeat bacterial cultures of blood, urine and cerebro-
spinal fluid were negative. Given the pneumonitis, massive
hepatosplenomegaly, thrombocytopenia, coagulopathy, and
lack of response to cefotaxime, CMV was suspected to be
the causative pathogen. Urine and endotracheal aspirate
cultures for CMV were positive, plasma CMV polymerase
chain reaction (PCR) showed a VL of 3 × 106 copies/ml,
and CMV was detected in the CSF by PCR. Cefotaxime
was discontinued and ganciclovir therapy was reinitiated
(6 mg/kg/dose IV q12h) 14 days after the onset of his de-
terioration; slow improvements in respiratory status and
thrombocytopenia were then observed. After 13 days of
therapy, the infant was stable from a cardiopulmonary
perspective; his CMV plasma VL at that time was 1865
copies/mL. The patient continued to improve and after
4 weeks of IV therapy he was switched to oral valgan-
ciclovir (16 mg/kg/dose q12h) when he no longer required
intravenous access for any other indication.
He was discharged home three weeks later, on valgan-
ciclovir, at 6 months of chronologic age, still requiring low
flow oxygen; at this time, his CMV plasma VL was 5771
copies/mL. The decision was made to continue oral anti-
viral therapy after discharge until his viral load became
undetectable, given his complicated history; ultimately, he
received 9 weeks of oral therapy and ~ 3 months total ther-
apy. He did not experience any significant complications
thought to be caused by his second treatment course of
ganciclovir/valganciclovir; his absolute neutrophil count hit
a nadir of 900/microL but recovered without any filgrastim
treatment or alteration to antiviral dosing. Laboratory
evaluation for immune deficiency performed at 11 months
chronologic age demonstrated that his immunoglobulin A
level was 0.31 g/L, immunoglobulin G level was 14.6 g/L,
and immunoglobulin M level was 0.95 g/L. The patient’s
CD4 count was 1530/microL (30%), CD8 count was 1580/
microL, and he had 23% CD19 B cells. Phytohemagglutinin
stimulation testing of T lymphocytes revealed a normal
response.
Conclusions
The clinical presentation and sequelae associated with con-
genital CMV disease have been described in detail; however,
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scribe an infant treated for congenital CMV infection who
later in infancy had a life-threatening episode of presumed
multi-organ CMV infection. We hypothesize the following:
first, that the episode of life-threatening illness that the pa-
tient experienced at four months chronologic age was
caused by CMV, and second, that this CMV infection was
due to reactivation of congenitally-acquired virus rather
than to a second, postnatally-acquired, infection.
We posit that CMV infection was responsible for the
infant’s clinical deterioration at four months of age be-
cause of the clinical picture of pneumonitis, hepatitis,
hepatosplenomegaly, thrombocytopenia, and coagulopathy;
furthermore, the patient progressively deteriorated while on
antibacterials, had a greatly elevated CMV plasma VL, and
had CMV detected in all fluids assayed with zero sterile-site
cultures positive for a bacterial pathogen. Other aetiologies
cannot be definitively excluded, however, as herpesviruses
can reactivate leading to DNAemia in the context of an
intercurrent infection. The CMV VL at the time of his late
clinical deterioration was not significantly different than the
VL after his first course of ganciclovir was prematurely
interrupted, though it was clearly higher than all the VLs
recorded subsequent to his re-treatment with ganciclovir.
The patterns of plasma CMV PCR VLs in infants with con-
genital infection subsequent to termination of therapy have
not been systematically studied, though Kimberlin et al.
documented a ~1 log increase in CMV VL in a small group
of infants two weeks after the discontinuation of 6 weeks of
ganciclovir therapy [5]; we note that CMV plasma VLs in
the millions are not commonly found in ‘asymptomatic’
term neonates with congenital CMV infection [6].
If the episode of clinical deterioration at four months of
age was indeed caused by CMV, what was the pathogenesis
of infection? There are two main possibilities: 1) recrudes-
cence of congenitally-acquired virus, or 2) acquisition of a
second, postnatal, infection. We posit that the first possibil-
ity is most likely; however, neither viral typing nor sequen-
cing were done. Frozen-thawed breast milk carries a low
risk of postnatal CMV transmission [7]; he also received
few transfusions and was given only leukoreduced irradi-
ated blood, so his risk of transfusion-associated CMV in-
fection can also be estimated to be extremely low [8].
As for the pathogenesis of recrudescence of congenital
infection, there are multiple possibilities: viral reactivation,
lack of initial response due to interruption of therapy,
ganciclovir-resistant virus, among others. The first – viral
reactivation – would appear to be most likely. There is no
evidence for ganciclovir resistance, given his clinical and
virologic improvement while on ganciclovir. His initial
treatment course was certainly not ‘standard’, but he re-
ceived over 8 weeks of appropriately-dosed IV ganciclovir
between the ages of 3 and 14 weeks, which we judged to
be sufficient at the time.Our case has potential implications for both diagnostic
testing and patient follow-up; had the diagnosis of recru-
descent CMV infection been considered sooner, we could
have more quickly initiated specific therapy and perhaps
reduced morbidity. To this end, it may be useful to moni-
tor plasma CMV VL at cessation of therapy, 2–4 weeks
later (to catch initial VL rebound), and then at the time of
any clinical deterioration/systemic illness of uncertain aeti-
ology, especially for babies not born at term.
This case also raises the question once again about the
appropriate duration of therapy for congenital CMV infec-
tion. Some authors have reported their experiences with
prolonging therapy in infants with congenital CMV infec-
tion [9,10]. As stated by Kimberlin et al., “…[rebound
of VL post-discontinuation of ganciclovir] provides a
rationale for the study of a treatment period longer than
the currently-used 6-week period” [5]. We extended anti-
viral therapy beyond 6 weeks to treat our patient’s CMV
recrudescence because of a possible ‘failure’ of the ini-
tial 6–9 week course of ganciclovir, the severity of his
illness, and an ongoing detectable CMV VL. An ongoing
multicentre trial comparing 6 weeks to 6 months of oral
valganciclovir will hopefully help define the benefits and
risks of longer treatment of symptomatic congenital CMV
infection (NCT00466817, www.clinicaltrials.gov). It must
be emphasized that treatment of congenital CMV infec-
tion often requires assiduous monitoring of clinical, bio-
chemical, and virologic indices, and therefore cannot be
easily protocolized.
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